Aicuris launces AiCubator to support early start-up who tackle AMR
by Jasmin Schubert
Anti-infectives specialist AiCuris GmbH invites academic groups or recently formed biotech start-ups with early stage projects in the antiviral or antibacterial field to apply for a resident status in AiCuris` AiCubator program. Three projects will be selected within the call of 2020 and will receive up to three years expert support and evaluation in topics such as pre-clinical and clinical drug development and insight into the pharmaceutical business. The aim is to help researchers and start-ups in early developmental phases with financing and business development advices to growth their idea to their own businesses.
The application criteria for the 2020 call are indications on Gram-negative resistance-breaking antibiotics, as well as targeted antiviral therapies for the therapy of herpes virus, adenovirus, hepatitis B cure and respiratory viruses.
Applicants can submit their proposals until 31 October 2020. The selected projects will be announced in mid-December and will start on 1 January 2021.
AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases.
Further information at: www.aicuris.com/148/PREP/AiCubator.htm